Biography and Research Information
OverviewAI-generated summary
Otis M. Davis's research focuses on cardiovascular function and risk factors, particularly within the context of chronic kidney disease (CKD). His work investigates the pharmacological effects of antiplatelet medications, comparing the efficacy of ticagrelor and clopidogrel in patients with advanced CKD. Studies have examined how these drugs inhibit platelet aggregation and influence inflammatory markers. Additionally, his research explores the relationship between platelet count, platelet volume, and the progression of CKD. Davis has published four scholarly works, with a total of 16 citations and an h-index of 2. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Nishank Jain, Jerry Ware, Yasir Rahmatallah, and Adam Corken.
Metrics
- h-index: 2
- Publications: 4
- Citations: 18
Selected Publications
-
Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD] (2024)
-
Platelet Count and Platelet Volume in Patients with CKD (2023)
-
Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease (2023)
-
Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Aggregation in Patients With Stages 4-5 CKD (2022)
Collaboration Network
Top Collaborators
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD]
- Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Aggregation in Patients With Stages 4-5 CKD
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Aggregation in Patients With Stages 4-5 CKD
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Platelet Count and Platelet Volume in Patients with CKD
- Platelet Count and Platelet Volume in Patients with CKD
- Platelet Count and Platelet Volume in Patients with CKD
Similar Researchers
Based on overlapping research topics